These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 9703784

  • 1. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM, Mallmann PK.
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Amifostine and hematologic effects.
    Sriswasdi C, Jootar S, Giles FJ.
    J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
    [Abstract] [Full Text] [Related]

  • 6. Future development of amifostine as a radioprotectant.
    Werner-Wasik M.
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [Abstract] [Full Text] [Related]

  • 7. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V.
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [Abstract] [Full Text] [Related]

  • 8. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1369-77. PubMed ID: 15050312
    [Abstract] [Full Text] [Related]

  • 9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL.
    Semin Oncol; 1999 Apr 01; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [Abstract] [Full Text] [Related]

  • 10. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 11. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL, Oster W.
    Int J Hematol; 2000 Dec 01; 72(4):425-35. PubMed ID: 11197208
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
    Werner-Wasik M, Langer C, Movsas B.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):47-51. PubMed ID: 15726523
    [Abstract] [Full Text] [Related]

  • 15. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG.
    Eur J Cancer Care (Engl); 2009 Mar 01; 18(2):116-23. PubMed ID: 19267726
    [Abstract] [Full Text] [Related]

  • 16. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
    Hospers GA, Eisenhauer EA, de Vries EG.
    Br J Cancer; 1999 May 01; 80(5-6):629-38. PubMed ID: 10360638
    [Abstract] [Full Text] [Related]

  • 17. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S, Hoffmanns H.
    Strahlenther Onkol; 1999 Nov 01; 175 Suppl 4():30-3. PubMed ID: 10584138
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB.
    Cancer; 2009 Oct 01; 115(19):4514-23. PubMed ID: 19634161
    [Abstract] [Full Text] [Related]

  • 19. Amifostine in reducing cisplatin toxicity.
    Markman M.
    Semin Oncol; 1998 Oct 01; 25(5):522-4. PubMed ID: 9783591
    [Abstract] [Full Text] [Related]

  • 20. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
    Fiorentini G, Giovanis P, Leoni M, De Giorgi U, Cariello A, Dazzi C, Caldeo A.
    Hepatogastroenterology; 2001 Oct 01; 48(38):313-6. PubMed ID: 11379297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.